Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2c receptor antagonist agomelatin (valdoxan)

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 111, Issue 9, 2011, Pages 32-35

  Tabeeva, G R ^a   Sergeev, A V ^a   Gromova, S A ^a  

^a NONE

Author keywords

Agomelatin (valdoxan); Melatonin; Migraine; Preventive treatment

Indexed keywords

AGOMELATINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; HEADACHE; HUMAN; MIGRAINE; NIGHT SLEEP; QUALITY OF LIFE;

EID: 80054744194     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Russian Source.
2. Russian Source.
3. Russian Source.
4. Russian Source.
5. Claustrat B., Brun J., Geoffriau M. et al. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997; 17: 511-517.
6. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
7. Eser D., Baghai T.C., Moller H.J. Evidence of agomelatine's antidepressant efficacy: the key points. Int Clin Psychopharmacol 2007; 22: Suppl 2: 15-19.
8. European Medicines Agency (2008). CHMP Assessment for Valdoxan. London 2008; Doc. Ref.: EMEA/655251/2008.
9. Evers S., Afra J., Frese A. et al. EFNS guideline on the drug treatment of migraine. Eur J Neurol 2009; 16: 9: 968-981.
10. Fornaro M., Prestia D., Colicchio S., Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010; 8: 3: 287-304.
11. Ghosh A., Hellewell J.S. A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Expert Opin Investig. Drugs 2007; 16: 1999-2004.
12. Gori S., Morelli N., Maestri M. et al. Sleep quality, chronotypes and preferential timing of attacks in migraine without aura. J Headache Pain 2005; 6: 258-260.
13. Hanoun N., Mocaer E., Boyer P.A. et al. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 2004; 47: 515-526.
14. Headache Classification Committee of the International Headache Society. The international classification of headache disorders (2nd edition). Cephalalgia 2004; 24: Suppl 1: 1-160.
15. Kasper S. Effect of agomelatine on rest-activity cycle in patients with major depressive disorder compared to sertraline. Int J Neuropsychopharmacol 2008; 11: Suppl 1: 193.
16. Lemoine P., Guilleminault C., Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723-1732.
17. Millan M.J., Gobert A., Lejeune F. et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-964.
18. Montgomery S.A., Kennedy S.H., Burrows G.D. et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-280.
19. Montgomery S.A., Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283-291.
20. Nagtegaal J.E., Laurant M.W., Kerkhof G.A. et al. Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. J Psychosom Res 2000; 48: 45-50.
21. Peres M.F., Sanchez del Rio M., Seabra M.L. et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 2001; 71: 747-751.
22. Peres M.F.P. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 2005; 25: 403-411.
23. Ramadan N.M. The link between glutamate and migraine. CNS Spectr 2003; 8: 446-449.
24. Servier Laboratories Ltd., 2009. Valdoxan (agomelatine) Summary of Prod.uct Characteristics 2010. http://emc.medicines.org.uk/medicine/21830/SPC/Valdoxan/)
25. Stahl S.M. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neurop-sycopharmacol 2007; 10: 575-578.
26. Stovner L.J., Andree C. Eurolight Steering Committee. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain 2008; 9: 3: 139-146.